Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Trimethobenzamide 300 Mg Caps 100 By Sun Pharma

Image 0 of Trimethobenzamide 300 Mg Caps 100 By Sun PharmaImage 1 of Trimethobenzamide 300 Mg Caps 100 By Sun Pharma

Trimethobenzamide 300 Mg Caps 100 By Sun Pharma

Call for Price

Trimethobenzamide 300 Mg Caps 100 By Sun Pharma This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD3515079/RXB10055078/RXa376012/RXA318367
Selling Size : 100
Selling UoM : EA
NDC: 53489-0376-01
UPC Barcode : 353489376013
Supplier: 0050001300 SUN PHARMACEUTICAL IND INC
Supplier Material : 037601
Generic Code : 049940 TRIMETHOBENZAMIDE HCL ORAL CAPSULE 300 M
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals

Have a question?

  Call for Price

Product Description.:

MUTUAL 401, MUTUAL 401
capsule , orange , oblong oblong
OpaqueBlack ink

Chemically, trimethobenzamide HCl is N-[p-[2-(dimethylamino)ethoxy]benzyl]-3,4,5trimethoxybenzamide monohydrochloride.

Capsules: Each 300-mg Tigan capsule for oral use contains trimethobenzamide hydrochloride equivalent to 300 mg. The capsule has an opaque purple cap marked ?Tigan? and an opaque purple body marked ?M079?. Inactive Ingredients: D&C Red No. 28, FD&C Blue No. 1, lactose, magnesium stearate, starch and titanium dioxide.

INDICATIONS

Tigan is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

SIDE EFFECTS

There have been reports of hypersensitivity reactions and Parkinson-like symptoms. There have been instances of hypotension reported following parenteral administration to surgical patients. There have been reports of blood dyscrasias, blurring of vision, coma, convulsions, depression of mood, diarrhea, disorientation, dizziness, drowsiness, headache, jaundice, muscle cramps and opisthotonos. If these occur, the administration of the drug should be discontinued. Allergic-type skin reactions have been observed therefore, the drug should be discontinued at the first sign of sensitization. While these symptoms will usually disappear spontaneously, symptomatic treatment may be indicated in some cases.